Arcutis Biotherapeutics Inc Asset Resilience Ratio
Arcutis Biotherapeutics Inc asset resilience ratio. Arcutis Biotherapeutics Inc (ARQT) has an Asset Resilience Ratio of 41.85% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See ARQT cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Arcutis Biotherapeutics Inc (2017–2025)
Asset resilience ratio of Arcutis Biotherapeutics Inc from 2017 to 2025. This chart shows how Arcutis Biotherapeutics Inc's Asset Resilience Ratio has changed over time. Read how much debt does Arcutis Biotherapeutics Inc carry for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Arcutis Biotherapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Arcutis Biotherapeutics Inc total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $204.43 Million | 41.85% |
| Total Liquid Assets | $204.43 Million | 41.85% |
Asset Resilience Insights
- Very High Liquidity: Arcutis Biotherapeutics Inc maintains exceptional liquid asset reserves at 41.85% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Arcutis Biotherapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Arcutis Biotherapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Shanghai Medicilon Inc
SHG:688202 |
Biotechnology | 6.69% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767 |
Biotechnology | 0.56% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.76% |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880 |
Biotechnology | 5.52% |
Arcutis Biotherapeutics Inc Asset Resilience Ratio by Year (2017–2025)
Arcutis Biotherapeutics Inc asset resilience ratio by year from 2017 to 2025. The table below shows the annual Asset Resilience Ratio data for Arcutis Biotherapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 41.13% | $178.07 Million | $432.97 Million | -3.76pp |
| 2024-12-31 | 44.89% | $156.62 Million | $348.89 Million | -8.85pp |
| 2023-12-31 | 53.74% | $183.46 Million | $341.37 Million | -25.48pp |
| 2022-12-31 | 79.23% | $355.95 Million | $449.27 Million | +8.03pp |
| 2021-12-31 | 71.20% | $290.61 Million | $408.15 Million | -2.34pp |
| 2020-12-31 | 73.54% | $219.36 Million | $298.27 Million | +38.10pp |
| 2019-12-31 | 35.44% | $37.93 Million | $107.01 Million | +12.85pp |
| 2018-12-31 | 22.60% | $11.55 Million | $51.10 Million | -- |
| 2017-12-31 | 0.00% | $0.00 | $3.82 Million | -- |
About Arcutis Biotherapeutics Inc
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. It also develops ZORYVE foam seborrheic dermatitis, and scalp and body psoriasis treatment; ARQ-234, a fusion protein that is a po… Read more